Back to search results

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE2

Conditions

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · T Acute Lymphoblastic Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

    Contact: Study coordinator (Kim Quach) · kquach@fredhutch.org · 206-606-8311
    Contact: Principal Investigator (Ryan D. Cassaday, MD)
Study leads

  • Ryan D. Cassaday, MD

    Principal Investigator

    Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov(opens in a new tab)